Novartis and Cleveland Clinic returned to fund the medical device maker's series D round, which increased its overall funding to $95m.
Autonomic Technologies, the US-based developer of a microstimulator treatment for headaches, closed a $38m series D round today backed by medical research firm Cleveland Clinic and pharmaceutical company Novartis.
Venture capital firm Edmond de Rothschild Investment Partners, syndicated with Forbion Capital Partners, led the round, which also included Kleiner Perkins Caufield and Byers (KPCB), InterWest Partners and Aberdare Ventures.
Autonomic’s lead product is a microstimulator that is being developed to treat autonomic disorders such as severe headaches. Its Pulsante device…
